Clinical Trial: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
Study Status: Completed
Recruit Status: RECRUITING
Condition: Mucopolysaccharidosis (MPS)
Study Type: INTERVENTIONAL
Official Title: An Open-label, Multicenter, Phase 4 Study to Assess the Effects of a Prophylactic Immune Tolerizing Regimen in MPS II Treatment-Naïve Patients Planned to Receive ELAPRASE Who Are at Risk of Developing
Brief Summary:
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter syndrome.In this open label, single arm study, all participants will receive ELAPRASE treatment and a prophylactic ITR.Participants will be treated with ELAPRASE for up to 104 weeks.The prophylactic ITR will start 1 day prior to the start of ELAPRASE.The prophylactic ITR will consist of a…
Read more